Allergic airway inflammation: Unravelling the relationship between IL-37, IL-18R and Tir8/SIGIRR

Expert Review of Respiratory Medicine

Volumn 9, Issue 6, 2015, Pages 739-750

  Lunding, Lars ^a   Schröder, Alexandra ^a   Wegmann, Michael ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Asthma; Caspase 1; Chronic inflammation; IL 18Ra; IL 37; inflammasome; Regulation; TH2 cells; Tir8 SIGIRR

Indexed keywords

INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 37; SINGLE IMMUNOGLOBULIN INTERLEUKIN 1 RECEPTOR; TOLL INTERLEUKIN 1 RECEPTOR 8; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; CYTOKINE; IL37 PROTEIN, HUMAN; INTERLEUKIN 1; TIR8 PROTEIN, HUMAN;

ALLERGIC AIRWAY INFLAMMATION; ALLERGIC ASTHMA; ALLERGIC DISEASE; CYTOKINE RELEASE; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IN VITRO STUDY; MOUSE MODEL; NONHUMAN; RESPIRATORY TRACT INFLAMMATION; REVIEW; ANIMAL; ASTHMA; DISEASE MODEL; IMMUNOLOGY; INFLAMMATION; RESPIRATORY TRACT ALLERGY;

ANIMALS; ASTHMA; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-18; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-18; RESPIRATORY HYPERSENSITIVITY;

EID: 84949097952     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2015.1109452     Document Type: Review

References (93)

1. Masoli M, Fabian D, Holt S, et al. Program GI for A (GINA). The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy. 2004;59(5):469-478.
2. Global Initiative for Asthma. Global strategy for asthma management and prevention [Internet]. [cited 2015 Apr]. Available from: www. gina. com
3. Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med. 2006;355(21):2226-2235.
4. Romanet-Manent S, Charpin D, Magnan A, et al. Allergic vs nonallergic asthma: what makes the difference? Allergy. 2002;57(7):607-613.
5. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372(9643):1107-1119.
6. Meyer EH, DeKruyff RH, Umetsu DT. T cells and NKT cells in the pathogenesis of asthma. Annu Rev Med. 2008;59:281-292.
7. Jacobsen EA, Taranova AG, Lee NA, et al. Eosinophils: singularly destructive effector cells or purveyors of immunoregulation? J Allergy Clin Immunol. 2007;119(6):1313-1320.
8. Jacoby DB, Costello RM, Fryer AD. Eosinophil recruitment to the airway nerves. J Allergy Clin Immunol. 2001;107(2):211-218.
9. Schaub B, Lauener R, von Mutius E. The many faces of the hygiene hypothesis. J Allergy Clin Immunol. 2006;117(5):969-977. quiz 978.
10. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118 (11):3546-3556.
11. Broide DH. Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J Allergy Clin Immunol. 2008;121(3):560-570. quiz 571-572.
12. Prakash Y, Thompson MA, Meuchel L, et al. Neurotrophins in lung health and disease. Expert Rev Respir Med. 2010;4 (3):395-411.
13. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117 (14):3720-3732.
14. Towne JE, Garka KE, Renshaw BR, et al. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem. 2004;279(14):13677-13688.
15. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. 2008;223:20-38.
16. O'Neill LAJ. The interleukin-1 receptor/ Toll-like receptor superfamily: 10 years of progress. Immunol Rev. 2008;226:10-18.
17. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-550.
18. Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science. 2003;300(5625):1524-1525.
19. Nakanishi K, Yoshimoto T, Tsutsui H, et al. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 2001;12(1):53-72.
20. Kunikata T, Torigoe K, Ushio S, et al. Constitutive and induced IL-18 receptor expression by various peripheral blood cell subsets as determined by anti-hIL-18R monoclonal antibody. Cell Immunol. 1998;189(2):135-143.
21. Hoshino K, Tsutsui H, Kawai T, et al. Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J Immunol Baltim Md 1950. 1999;162(9):5041-5044.
22. Iikura M, Suto H, Kajiwara N, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Investig J Tech Methods Pathol. 2007;87(10):971-978.
23. Yoshimoto T, Tsutsui H, Tominaga K, et al. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci U S A. 1999;96 (24):13962-13966.
24. Gutzmer R, Langer K, Mommert S, et al. Human dendritic cells express the IL-18R and are chemoattracted to IL-18. J Immunol Baltim Md 1950. 2003;171 (12):6363-6371.
25. Kitasato Y, Hoshino T, Okamoto M, et al. Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2004;31(6):619-625.
26. Lu Y, Wang W-J, Leng J-H, et al. Inhibitory effect of triptolide on interleukin-18 and its receptor in rheumatoid arthritis synovial fibroblasts. Inflamm Res Off J Eur Histamine Res Soc Al. 2008;57 (6):260-265.
27. Do DV, Ong CT, Khoo YT, et al. Interleukin-18 system plays an important role in keloid pathogenesis via epithelialmesenchymal interactions. Br J Dermatol. 2012;166(6):1275-1288.
28. Albrecht EA, Chinnaiyan AM, Varambally S, et al. C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol. 2004;164 (3):849-859.
29. Tucci M, Quatraro C, Dammacco F, et al. Increased IL-18 production by dendritic cells in active inflammatory myopathies. Ann N Y Acad Sci. 2007;1107:184-192.
30. Novick D, Kim SH, Fantuzzi G, et al. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity. 1999;10(1):127-136.
31. Novick D, Schwartsburd B, Pinkus R, et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine. 2001;14(6):334-342.
32. Kim S-H, Azam T, Novick D, et al. Identification of amino acid residues critical for biological activity in human interleukin-18. J Biol Chem. 2002;277 (13):10998-11003.
33. Kim SH, Azam T, Yoon DY, et al. Sitespecific mutations in the mature form of human IL-18 with enhanced biological activity and decreased neutralization by IL-18 binding protein. Proc Natl Acad Sci U S A. 2001;98(6):3304-3309.
34. Corbaz A, ten Hove T, Herren S, et al. IL-18-binding protein expression by endothelial cells and macrophages is upregulated during active Crohn's disease. J Immunol Baltim Md 1950. 2002;168 (7):3608-3616.
35. Paulukat J, Bosmann M, Nold M, et al. Expression and release of IL-18 binding protein in response to IFN-gamma. J Immunol Baltim Md 1950. 2001;167 (12):7038-7043.
36. Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995;378(6552):88-91.
37. Puren AJ, Razeghi P, Fantuzzi G, et al. Interleukin-18 enhances lipopolysaccharide-induced interferon-gamma production in human whole blood cultures. J Infect Dis. 1998;178(6):1830-1834.
38. Hoshino T, Kawase Y, Okamoto M, et al. Cutting edge: IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J Immunol Baltim Md 1950. 2001;166(12):7014-7018.
39. Ho LH, Ohno T, Oboki K, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgEFcepsilonRI signals. J Leukoc Biol. 2007;82(6):1481-1490.
40. Kondo Y, Yoshimoto T, Yasuda K, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol. 2008;20(6):791-800.
41. Sawada M, Kawayama T, Imaoka H, et al. IL-18 induces airway hyperresponsiveness and pulmonary inflammation via CD4+ T cell and IL-13. PloS One. 2013;8(1):e54623.
42. Wild JS, Sigounas A, Sur N, et al. IFNgamma-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma. J Immunol Baltim Md 1950. 2000;164 (5):2701-2710.
43. Yoshimoto T, Mizutani H, Tsutsui H, et al. IL-18 induction of IgE: dependence on CD4+ T cells, IL-4 and STAT6. Nat Immunol. 2000;1(2):132-137.
44. Hoshino T, Yagita H, Ortaldo JR, et al. In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+ T cells. Eur J Immunol. 2000;30 (7):1998-2006.
45. Koch KN, Hartung ML, Urban S, et al. Helicobacter urease-induced activation of the TLR2/NLRP3/IL-18 axis protects against asthma. J Clin Invest. 2015;125 (8):3297-3302.
46. Oertli M, Sundquist M, Hitzler I, et al. DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J Clin Invest. 2012;122 (3):1082-1096.
47. Cheng D, Hao Y, Zhou W, et al. The relationship between interleukin-18 polymorphisms and allergic disease: a metaanalysis. BioMed Res Int. 2014;2014:290687.
48. Wu H, Romieu I, Shi M, et al. Evaluation of candidate genes in a genome-wide association study of childhood asthma in Mexicans. J Allergy Clin Immunol. 2010;125(2):321-327. e13.
49. Zhu G, Whyte MKB, Vestbo J, et al. Interleukin 18 receptor 1 gene polymorphisms are associated with asthma. Eur J Hum Genet EJHG. 2008;16 (9):1083-1090.
50. Imaoka H, Takenaka S, Kawayama T, et al. Increased serum levels of soluble IL-18 receptor complex in patients with allergic asthma. Allergol Int Off J Jpn Soc Allergol. 2013;62(4):513-515.
51. Kuribayashi K, Kodama T, Okamura H, et al. Effects of post-inhalation treatment with interleukin-12 on airway hyper-reactivity, eosinophilia and interleukin-18 receptor expression in a mouse model of asthma. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2002;32(4):641-649.
52. Lewis EC, Dinarello CA. Responses of IL-18-and IL-18 receptor-deficient pancreatic islets with convergence of positive and negative signals for the IL-18 receptor. Proc Natl Acad Sci U S A. 2006;103 (45):16852-16857.
53. Gutcher I, Urich E, Wolter K, et al. Interleukin 18-independent engagement of interleukin 18 receptor-alpha is required for autoimmune inflammation. Nat Immunol. 2006;7(9):946-953.
54. Riva F, Bonavita E, Barbati E, et al. TIR8/SIGIRR is an interleukin-1 receptor/toll like receptor family member with regulatory functions in inflammation and immunity. Front Immunol. 2012;3:322.
55. Thomassen E, Renshaw BR, Sims JE. Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine. 1999;11(6):389-399.
56. Lech M, Garlanda C, Mantovani A, et al. Different roles of TiR8/Sigirr on toll-like receptor signaling in intrarenal antigenpresenting cells and tubular epithelial cells. Kidney Int. 2007;72(2):182-192.
57. Garlanda C, Riva F, Polentarutti N, et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci U S A. 2004;101(10):3522-3526.
58. Bulek K, Swaidani S, Qin J, et al. The essential role of single Ig IL-1 receptorrelated molecule/Toll IL-1R8 in regulation of Th2 immune response. J Immunol Baltim Md 1950. 2009;182 (5):2601-2609.
59. Adib-Conquy M, Adrie C, Fitting C, et al. Up-regulation of MyD88s and SIGIRR, molecules inhibiting Toll-like receptor signaling, in monocytes from septic patients. Crit Care Med. 2006;34 (9):2377-2385.
60. Wald D, Qin J, Zhao Z, et al. SIGIRR, a negative regulator of Toll-like receptorinterleukin 1 receptor signaling. Nat Immunol. 2003;4(9):920-927.
61. Qin J, Qian Y, Yao J, et al. SIGIRR inhibits interleukin-1 receptor-and tolllike receptor 4-mediated signaling through different mechanisms. J Biol Chem. 2005;280(26):25233-25241.
62. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23 (5):479-490.
63. Barry J, Loh Z, Collison A, et al. Absence of Toll-IL-1 receptor 8/single immunoglobulin IL-1 receptor-related molecule reduces house dust miteinduced allergic airway inflammation in mice. Am J Respir Cell Mol Biol. 2013;49(3):481-490.
64. Busfield SJ, Comrack CA, Yu G, et al. Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics. 2000;66(2):213-216.
65. Kumar S, McDonnell PC, Lehr R, et al. Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem. 2000;275 (14):10308-10314.
66. Pan G, Risser P, Mao W, et al. IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine. 2001;13(1):1-7.
67. Smith DE, Renshaw BR, Ketchem RR, et al. Four new members expand the interleukin-1 superfamily. J Biol Chem. 2000;275(2):1169-1175.
68. Nold MF, Nold-Petry CA, Zepp JA, et al. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11 (11):1014-1022.
69. Bufler P, Azam T, Gamboni-Robertson F, et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci U S A. 2002;99(21):13723-13728.
70. Kumar S, Hanning CR, Brigham-Burke MR, et al. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine. 2002;18(2):61-71.
71. Taylor SL, Renshaw BR, Garka KE, et al. Genomic organization of the interleukin-1 locus. Genomics. 2002;79(5):726-733.
72. Bulau A-M, Nold MF, Li S, et al. Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses. Proc Natl Acad Sci U S A. 2014;111 (7):2650-2655.
73. Di Stefano A, Caramori G, Barczyk A, et al. Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. Thorax. 2014;69(6):516-524.
74. Ye L, Jiang B, Deng J, et al. IL-37 alleviates rheumatoid arthritis by suppressing IL-17 and IL-17-triggering cytokine production and limiting Th17 cell proliferation. J Immunol Baltim Md 1950. 2015;194(11):5110-5119.
75. Liu W, Deng L, Chen Y, et al. Antiinflammatory effect of IL-37b in children with allergic rhinitis. Mediators Inflamm. 2014;2014:746846.
76. Sharma S, Kulk N, Nold MF, et al. The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J Immunol Baltim Md 1950. 2008;180(8):5477-5482.
77. McNamee EN, Masterson JC, Jedlicka P, et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci U S A. 2011;108(40):16711-16716.
78. Bulau A-M, Fink M, Maucksch C, et al. In vivo expression of interleukin-37 reduces local and systemic inflammation in concanavalin A-induced hepatitis. ScientificWorldJournal. 2011;11:2480-2490.
79. Patel FJ, Volkmann DT, Taylor GW, et al. IL-37 reduces inflammatory response after cerebral ischemia and reperfusion injury through down-regulation of pro-inflammatory cytokines. Cytokine. 2014;69(2):234-239.
80. Luo Y, Cai X, Liu S, et al. Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci U S A. 2014;111 (42):15178-15183.
81. Ballak DB, Li S, van Diepen JA, et al. 12: IL-37 protects against obesity-induced inflammation and insulin resistance. Cytokine. 2013;63(3):245-246.
82. Teng X, Hu Z, Wei X, et al. IL-37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production. J Immunol Baltim Md 1950. 2014;192(4):1815-1823.
83. Gao W, Kumar S, Lotze MT, et al. Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J Immunol Baltim Md 1950. 2003;170(1):107-113.
84. Li S, Neff CP, Barber K, et al. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proc Natl Acad Sci U S A. 2015;112(8):2497-2502.
85. Sakai N, Van Sweringen HL, Belizaire RM, et al. Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterol Hepatol. 2012;27 (10):1609-1616.
86. Wu B, Meng K, Ji Q, et al. Interleukin-37 ameliorates myocardial ischaemia/ reperfusion injury in mice. Clin Exp Immunol. 2014;176(3):438-451.
87. Moretti S, Bozza S, Oikonomou V, et al. IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis. PLoS Pathog. 2014;10(11): e1004462.
88. Li Y, Wang Z, Yu T, et al. Increased expression of IL-37 in patients with Graves' disease and its contribution to suppression of proinflammatory cytokines production in peripheral blood mononuclear cells. PloS One. 2014;9(9):e107183.
89. Raedler D, Ballenberger N, Klucker E, et al. Identification of novel immune phenotypes for allergic and nonallergic childhood asthma. J Allergy Clin Immunol. 2015;135(1):81-91.
90. Lunding L, Webering S, Vock C, et al. IL-37 requires IL-18R? and SIGIRR/IL-1R8 to diminish allergic airway inflammation in mice. Allergy. 2015;70 (4):366-373.
91. Nold-Petry CA, Lo CY, Rudloff I, et al. IL-37 requires the receptors IL-18R? and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol. 2015;16(4):354-365.
92. Ye L, Ji L, Wen Z, et al. IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity. J Transl Med. 2014;12:69.
93. Imaeda H, Takahashi K, Fujimoto T, et al. Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol. 2013;172 (3):410-416.